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Abstract - Eye is a unique organ which exerts various 
limitations for the delivery of drug due to its 
physiology barriers. Therefore, the posterior part of 
the eyes remains a major concern for formulation 
scientists to develop ocular drug delivery system 
which can overcome the barriers of theeye and 
provide local or systemic effect with immediate or 
sustained release dosage forms. Conventional 
ophthalmic dosage forms such as eye drop, ointment 
and gel provide low bioavailability and less pre-
corneal drug residence time due to nasolacrimal 
drainage of the eyes. The major challenge is to 
formulate a system to improve the contact time of the 
drug in eyes. This is achieved by in situ gel system 
where the drugs are incorporatedwith various types of 
polymers which exhibit solution to gel phase 
transition. An in situ gelling technique provides 
greater bioavailability by resisting ocular drainage 
leading to longer residence time. This paper proposes 
the formulation of in situ gels for effective delivery 
of Erythromycin used to treat conjunctivitis and to 
evaluate dosage form characteristic such as pH, 
gelling capacity, gel strength, sterility testing, drug 
content, in vitro diffusion study, antibacterial activity 
and accelerated stability studies to ensure the safety 
and stability of the dosage form. Hence an attempt 
will be made to develop novel in situ gelling systems 
using Erythromycin, antimicrobial agent as a 
promising alternative to the conventional dosage 
forms for the effective treatment of various eye 
infections. 
 
Keywords--In situ gel; ophthalmic; conjunctivitis; 
Erythromycin. 
 
I. INTRODUCTION 
The eye is a complex sensory organ design 
differently from other organs from its anatomy and 
physiology point of view. Unique anatomical and 
physiological features of eye make it impermeable to 
foreign particles.There are various dosage forms for 
ocular drug delivery but due to strong protective 
mechanism and barriers exerted by the eyes the 
ocular drug absorption and penetration especially into 
the posterior part of the eyes in desired therapeutic 
concentrations is not achieved successfully.  
The cornea of the eye (Figure 1)iscomposed of the 
epithelium, endothelium, and inner stromawhichactas 
the main barrier for the ocular absorption of drugs. 
The outer epithelium layer acts as a barrier for the 
penetration of hydrophilic drug whilethe inner stroma 
act as a barrier for the drugs which is 
hydrophobic.The lipophilic –hydrophilic- lipophilic 
nature of the tissues contributes to poor corneal 
penetration and permeability of drugs.Secretion of 
lachrymal fluids and blinking actionarethe natural 
mechanisms that prevent eyes from drying and 
eliminate all foreign substances being introduced into 
the conjunctival sac.A thusonly small portion of the 
installed drug will be delivered to the anterior 
segment of the eyes whereas most of it will be lost 
because of spillage and drainage through the 
nasolacrimal duct. 
Lisa (2015)stated thatonlyless than 5% intraocular 
bioavailability is achieved by the common topical 
ophthalmic dosage forms. Therefore, the major 
challenge for the formulator is to develop an 
ophthalmic novel drug delivery system without 
damaging the natural mechanism and barriers of the 
eyes at the same time achieving effective ocular drug 
concentration at the site of action while improving 
the residence time of the drugs in eyes. 
 
II.    LIMITATIONS OF CONVENTIONAL 
OCULAR DOSAGE FORMS 
Commonly the conventional ophthalmic drug 
delivery system is available in the form of eye drops, 
ointment, suspension and ocular inserts. Eye drops 
are mostly being prescribed out of all marketed 
ocular preparation; in fact, almost 90% of the 
ophthalmic formulations are available in the form of 
eye drops (Sampathetal.,2012). Eye drops are 
relatively easy to be introduced into the eyes for 
various eye diseases. Howeverelimination and rapid 
spillage of the drug from the precorneal area of the 
eyes upon installation due to nasolacrimal drainage 
leads to poor bioavailability and low therapeutic 
effect of the drug.Repeatedinstallation of high 
concentration drug will result in several side effects 
and damage the eye tissues. Frequent blinking of the 
eyes also drains out the drug at a higher rate.  
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GouravRajoriaand ArushiGupta(2012) claimed that 
the topical ophthalmic medication only absorbs 
approximately 5 to 7 minutes upon installation into 
the eyes and mostly not more than 2% of the 
medication is being absorbed and results in low 
bioavailability. Eye ointments are the next most 
popular preparations which increasecontact time of 
the drug in eyes but has some limitations such as 
greasy preparation and sticking of the eyelids which 
lead to low patient compliance, occasional irritation, 
discomfort and blurred vision. Conversely, the 
advanced ocular delivery system such as ocular 
inserts provides prolonged action dosage form but not 
widely accepted by patients because need to be 
inserted into the eyes, thushave low patient 
compliance. Other dosage forms, benefits, and 
drawbacks of conventional ophthalmic dosage forms 
are summarised in Table 1. 
 
III. IN SITU DRUG DELIVERY SYSTEM 
A novel drug delivery system with the use of natural 
or synthetic polymers that undergoes phase transition 
from solution to gel upon insertion into the cul-de-sac 
due to the response of the physiochemicalnature of 
the ophthalmic fluids (GouravRajoria and Arushi 
Gupta,2012). Gelation is triggered by few parameters 
such as pH, temperature, solvent exchange and ions 
which will form achemical or psychical cross linking 
between the polymeric materials used resulting in the 
formation of gel. The gel formed must be able to 
withstand the shear forces in the cul-de-sacandmust 
be less affected by corneal drainage.  The gel forming 
polymers act as rate controlling polymers which 
demonstrate prolonged drug release and improve 
theocular bioavailability of the drug (Mane Kirti and 
Dhole Shashikant, 2014).There are no limitations 
reported by any researcher on the in situgels as drug 
delivery system however, thehigh viscosity of the gel 
may cause blurred vision compared to the 
conventional ocular dosage forms. Therefore, the 
primary objective of the proposed study is to develop 
an antibacterial in situ ophthalmic gel as a less 
viscous free flowing fluid to overcome this 
problem.Erythromycin is a wide spectrum antibiotic 
under macrolide group of antibiotics which is 
commonly used as alternatives to patients having 
allergy to penicillin. Erythromycin is used to treat 
ocular bacterial infections such as trachoma and 
conjunctivitiscaused by Staphylococcus aureus, 
Chlamydia trachomatis and Neisseriagonorrhoeae. 
Erythromycin inhibits the cell membrane of the 
bacteria by reversibly binding to 50s subunit of 
ribosome without damaging the nuclei acid synthesis 
(KaulShwetaet al.,2012).This drug is stable and well 
established based on the pharmacological studies and 
available as 0.5% ophthalmic ointment in the market. 
Thus, the present study was aimed at developing an 
in situ gelling system for the effective delivery of 
Erythromycin with increased bioavailability through 
prolonged contact time. 
IV. BENEFITS OF IN SITU DRUG 
DELIVERY SYSTEM 
Compared to other ocular dosage forms, in situ drug 
delivery system has numerous benefits over the 
conventional ophthalmic dosage forms such as 
promotes bioavailability, less affected by 
nasolacrimal drainage thereby reduces absorption 
into the eye tissues and prevents thesystemic adverse 
effect. This novel drug delivery system combines 
both solution and gel which ease the introduction of 
formulation into the eyes and increases patient 
compliance (Figure 2).Furthermore, reduces 
thefrequency of dosing as the in situ gel retains the 
contact time of drug in the eye and effective 
therapeutic will be achieved. According toHimanshu 
Gupta et al.,(2015) the plain eye drop of 
Sparfloxacineliminated out quickly from the corneal 
surface of the eye compared to the Sparfloxacin 
developed as in situ gel formulation which showed 
sustained release of drug for a longer period and 
enhanced bioavailability (Figure 3). 
 
V. APPROACHES FOR IN 
SITUDELIVERY SYSTEM 
In situ gel formulation will be developed as less 
viscous free flowing liquid when exposing to the 
stimuli’s, solution converts into aviscoelastic gel. 
Various approaches for achieving in situ gelling 
systemarepHdependent system, ion dependentsystem, 
and temperature dependentsystem. Formulations 
based on the different approaches are: 
 
A. pH dependent system  
The pH changes trigger the formation of the solution 
to get such systems are formulated using pH sensitive 
polymers. When the sterile solutions are exposed to 
the pH of the eyes it undergoes aphase transition 
from solution to gel. Example of pH dependent 
polymers are Carbopol or Carbomer its derivatives. 
As the external pH increases the hydrogel swells and 
convert to form gel. 
 
B. Temperature dependent system 
Thermal dependent system is a great approach of 
thegelling system because the gelling is achieved 
without any great difficulties and easy to control. The 
mechanism of gelation occurs as the external 
temperature increases, the polymers undergo 
desolvation, increases micellar aggregation and 
increases polymeric network entanglement to form a 
highly viscous gel. Temperature sensitive polymers 
are Poloxamer ,Chitosan and Hydroxypropyl Methyl 
Cellulose (HPMC). 
 
C. Ion dependent system 
Phase transitions from solution to gel occur when 
exposed to the changes by ionic strength. Gelation is 
triggered when the anionic polymers comes in 
contact with the cations present in the tear fluid, 
interaction takesplace, and it converts to form gel. 
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Gelrite and Sodium Alginate are the examples of ion 
sensitive polymers.Figure 4 shows the development 
of in situ gel based on the ion dependent system, 
where the gellan gum (gelrite) undergoes aphase 
transition from solution to gel when in contact with 
artificial tear fluid. 
Following are the various approaches as reported in 
the literature.  
 Eaga Chandra Mohan et al., (2009) prepared 
and evaluated in situ gel for Ciprofloxacin, an 
antibacterial agent for the treatment of ocular 
bacterial infections. 
 Such as dacryocystitis, bacterial 
conjunctivitis, corneal ulceration and blepharitis by 
using 3 different polymers which are pH-triggered, 
temperature reversible and ion activated in 
situgellation. Carbopol 940 in combination with 
HPMC, Pluronic F-127 (14%) in combination of 
HPMC (1.5%) and Gellan gum was used as different 
approaches in thegelling system. Formulation 
obtained was stable, non irritant, therapeutically 
effective and provide sustained release of the drug for 
6 hours. Thus, the developed system can be a 
replacement for conventional eye drops. 
 SindhuAbrahamet al., (2009) prepared and 
characterized ion-activated in situ gel with 
antibacterial agent, Ofloxacin. Polymers used were 
sodium alginate in combination with HPC (Hydroxy 
Propyl Cellulose). In vitrodrugrelease, studies 
showed that Alginate or HPC solution alone was poor 
in retaining the drug compared to the alginate/HPC 
solution which showed theoptimum result. The 
formulated in situ gel achieved prolong drug release 
over a period of 8 hours, reduced frequency of drug 
administration, improved patient compliance and can 
be served as analternative to the conventional 
ophthalmic drops, economically and industrially 
orientated. 
 Yuejiang Liuet al., (2010)designed ion-
activated in situ gelling system for ophthalmic 
delivery of marine. Gelrite, alginate and gelrite / 
alginate was used and evaluated for rheological 
properties. Excellent gel strength was achieved by the 
mixture of 0.2% Gelrite and 0.6% alginate solutions 
which provide a better capability to retain drug in 
both in vitro release and in vivo pharmacological 
studies. The tested formulation was found to be non-
irritant in the ocular irritancy test. The authors 
concluded that gelrite/alginate mixture can be used as 
an in situ gelling vehicle to enhance ocular retention. 
 Kavitha and Rajas (2011) developed 
controlled release in situ ophthalmic gels of 
Levofloxacin hemihydrates by using gelrite for the 
treatment of various ocular bacterial infections. Six 
different in situ gelswere prepared by dispersing 
gelrite with increasing polymeric concentration. The 
in situ gel was tested for clarity, pH, drug content, 
sterility test, gelling property, rheological studies, 
ocular testing and in vitro drug release studies. The 
developed formulation showed sustained drug release 
for 8 hours,optimumuniformity, and spreadability. 
The formulation was found to be improved 
bioavailability and increased pre-corneal drug 
residence time. 
 Abdullah Khan et al., (2013) designed in 
situ gelling system for Gatifloxacin, an antibacterial 
agent using hydroxypropyl cellulose and sodium 
alginate as the polymers to increase the pre-corneal 
resident time andophthalmic bioavailability of the 
drug. The designed in situ gel was evaluated for 
various physical parameters such as pH, viscosity, 
drug content, clarity, sterility, and in vitro drug 
release. They observed the formulated gel was 
transparent, good spreadability, pH range of 6.8 to 
7.1 and uniform in consistency.  
Result found was increased in the concentration of 
the polymer sodium alginate, therefore sustained drug 
release from the formulation for up to 12 hours. Thus 
the formulation of ophthalmic in situ gel for 
Gatifloxacin improves the bioavailability of the drugs 
on the precorneal area. 
 Bhatia et al., (2013)developedin situ gels 
based on thermo-reversible poloxamer 407 
polymeralong with different mucoadhesive polymers 
such as sodium carboxy methyl cellulose (Na CMC), 
HPMC K100Lvp, and polyvinyl pyrrolidone (PVP) 
K30. Cold method was used to formulate the thermo-
reversible mucoadhesive gels of Azithromycin. The 
in situ gels were evaluated for ocular irritation, 
sterility, stability, antimicrobial activity and in 
vivocorneal permeation studies. They found that the 
in situ gel can be safely installed into the eye without 
any adverse effects; enhance stability and good 
antibacterial activity compared to the marketed 
formulation of Azithromycin. 
 Rathod and Patel (2013) designed and 
testedion sensitive in situ gelling system for 
antibacterial agent Norfloxacin, by using Sodium 
alginate in combination with Hydroxypropyl Methyl 
Cellulose (HPMC K4M) which acted as a viscosity 
enhancing agent and gelling agent. The formulated 
gel was tested for viscosity, gelling capacity, 
antimicrobial activity, stability testing, in vitro drug 
release, ocular irritation, clarity, pH and drug content. 
The evaluation result obtained was satisfactory and 
developed was found to be therapeutically effective, 
stable, non-irritant, and provided prolong drug 
release. The authors concluded that the prepared 
formulation can be a viable alternative to 
conventional eye drops. 
 Reddy and Ahmed (2013) formulated pH 
based ocular in situgelling systems with 
Sparfloxacinby utilizing HPMC and carbopol as the 
gelling agents. The developed gel was examined for 
drug content, gelling strength, clarity, viscosity, in 
vitro drug release study and in vivo using animal 
models for antibacterial properties. The results 
obtained were optimum and formulated in situ gel 
can be designed to improve patient compliance and 
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as substitute to the marketed conventional drug 
delivery system. 
 
D. Designing In Situ gelling System Of 
Erythromycin 
In this research, in situdrug delivery system will 
developed based of 2 approaches namely ion 
dependentand temperature dependentsystem using 
polymers such as Chitosan, Sodium Alginate and 
Hydroxypropyl Methyl Cellulose (HPMC). Drug and 
polymers along with the excipients will be 
characterized for their identity and purity.  
The polymeric solution will be prepared by 
dispersing Chitosan, Sodium Alginate and HPMC 
into the solvent at various compositions by 
continuous stirring using amagnetic stirrer to prevent 
excessive formation of lumps. Erythromycin powder 
(0.5% w/v) will be dissolved in diluted acetic acid 
and phosphate buffers 0.1 N NaOH will be used to 
adjust the pH 6.5.Benzalkonium chloride (0.02% v/v) 
will be added to the solution as preservative agent. 
Thus, the drug Erythromycin will be 
incorporatedwith the various polymeric solutionsand 
purified water will beadded to make up the final 
volume to 100ml under constant stirring to obtain 
uniform solutions. The prepared solution will be 
filtered using 0.2m filter paper and sterilized in 
anautoclave at 121°C and 15 psi for 15 minutes 
(Abdul Malik and Satyananda,2014). 
 
VI. EVALUATION OF IN SITU GELLING 
SYSTEM 
 
The followings are the evaluation parameters for 
Erythromycin in situ gel formulation: 
 Visual appearance and clarity: The prepared 
gel formulationswill be checked for clarity and 
appearance by rotating the solution in a glass vial and 
inverted under the light behind the black and white 
background to test for its colour, odour and inverted 
twice to detect any presence of suspended particulate 
(Abdullah Khan et al.,2013). 
 pH measurement: pH of the formulations 
will be measured using digital pH meter. 
 Gelling capacity: Determination of in vitro 
gelation is vital to identify the prepared formulation 
are ideal to be used as in situ gels. Gelling will be 
determined by placing a drop of the polymeric 
solution incorporated with thedrug in different ratios 
into the 1ml freshly prepared artificial tear fluid 
which is calibrated at 34°C to trigger gelation.The 
time taken for the solution to convert into gel and 
formed gel to dissolve will be measured (Abdul 
Malik and Satyananda, 2014). 
 Rheological property: Viscosity is a 
significant element to determine the sustained release 
of the drug in the eyes. The Erythromycin solution 
will be placed in the prepared artificial tear fluid and 
allowed to form gel. Then, the formed gel will be 
testfor viscosity by using Brooke field viscometer 
RVT model (SindhuAbraham et al.,2009). 
 Sterility study:Sterility parameter is an 
important key of evaluation because ocular 
preparations are intended to be sterile dosage forms. 
The test for sterility will be carried out aseptically 
according to British Pharmacopoeia by inoculating 
2ml of the sample formulation to fluid thioglycolate 
medium (20ml) and soyabean casein digest medium 
(20ml). Both mediums will be incubated for 14 days, 
fluid thioglycolate medium at 30-35°C and soyabean 
casein digest medium incubated at 20-25°C to 
identify the culture of anaerobic and aerobic 
microbial growth (Abdullah Khan et al.,2013). 
 Stability study: Prepared sample will be 
subjected to stability studies, stored at anaccelerated 
temperature such as 40°C ± 1.0°C and 75% RH to 
evaluate the end of storage period for clarity, 
viscosity, pH,drug content,gelling capacity and in 
vitrodrug release (Mahesh NS and Manjula BP, 
2012). 
 In vitro drug release study: In vitro drug 
release of Erythromycin will be determined by 
diffusion technique using the classical laboratory 
method with simple modifications of theopen ended 
glass tube. A cellophane membrane is tied to the 
open end of the cylinder which resembles as donor 
compartment. 1ml of the prepared formulation will 
be placed in the donor compartment over the 
diffusion cellophane membrane which will be pre 
soaked in the diffusion medium. The diffusion 
cellophane membrane act as eye tissues where the 
diffusion of the drug take place and the entire surface 
of the membrane will be kept in contact with receptor 
compartment containing 25ml of artificial tear fluid 
in 100ml beaker. The medium in the receptor 
compartment is stirred continuously with amagnetic 
stirrer and maintained at 37°C to ensure the medium 
touches the membrane constantly. 1ml of thesample 
from the receptor compartment will be withdrawn to 
analyze the drug content using UV 
Spectrophotometer at 285nm.The liquid withdrawn 
will be replaced by freshly prepared and warmed 
artificial tear fluid into the receptor compartment 
(KaulShwetaet al., 2012). 
 In vitro microbiological study: Prepared 
formulation will be evaluated for amicrobiological 
study to determine the antibacterial properties of 
Erythromycin in comparison with the existing 
marketed formulation against Staphylococcus aureus 
by using cup plate method. All procedures will be 
carried out under aseptic condition. 20ml of nutrient 
agar will be inoculated with 0.2ml of Staphylococcus 
aureus along with 7µl of artificial tear fluid and 
allowed to solidify in the petri dish. Then with the 
help of sterile borer,cups of 4mm diameter will be 
made on the solidified nutrient agar. The developed 
formulation (25µl) will be poured into the cups made 
and incubate for 24 hours to observe the zone of 
inhibition produced by the developed formulation the 
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zone of inhibition will be compared with that of 
marketed formulation under similar 
conditions(Bhatia et al., 2013). 
 
VII. DISCUSSION 
Better understanding of the limitations exerted by the 
anatomicaland physiologicalbarriersof the eyes 
brings more advancement in the development of safe 
and effective ocular drug delivery system. Hence the 
focus of interest of drug delivery scientistsisto 
overcome these anatomical and physiological barriers 
of the eye.  In situ gels will be a promising approach 
to enhance bioavailability and sustained release of the 
drug thereby ensuring theeffective therapeutic 
outcome. Exploitation of the polymers for sustained 
release properties contributes to various advantages 
for in situ gelling system which overcome the 
limitations associated with conventional ocular 
preparations. The composition and ratios of the 
polymeric solution is vital to determine the viscosity 
and gelling strength of the formulation.in situ gels are 
biodegradable and easy to introduce into the eyes 
without the need to remove after the drug is 
completed released from the dosage form thus 
improves patient compliance. Sustained release of 
Erythromycin from the in situ gel also reduces the 
frequency of higher concentration of antibiotic 
dosing which may lead to greater systemic side 
effects. Besides that, the methodology adopted for the 
development of novelin situ gel is simple and cost 
effective. 
 
VIII. CONCLUSION 
In a nut shell, this study proposes the development of 
novelasin situ gels for effective ocular delivery of 
Erythromycin through prolonged contact time and 
enhanced bioavailability.In situ gelling system has 
tremendous advantages over the ocular conventional 
dosage form. The benefits are less adverse effect, 
increase patient compliance, not affected by 
nasolacrimal drainage, increased drug contact time 
and reduced frequency of dosing, besides that it is 
easy to apply and also biodegradable. Considering all 
the benefits, in situgelling system will be a viable 
drug delivery system for the delivery of therapeutic 
agents to combat various ocular diseases and serve as 
an alternative to conventional ophthalmic dosage 
formsboththerapeuticallyand commercially. 
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FIGURE 1: Anatomy of human eye. Source from Mane Kirti and Dhole Shashikant(2014). 
 
                        
FIGURE 2:  Advantages of in situ gelling system adapted from Pallaviet al., (2015). 
 
BENEFITS OF IN SITU GELLING 
SYSTEM
Sustained release ocular prepration
Avoid nasolacrimal drainage
Improves bioavailability of drug
Precise dosing and reduce frequency in dosing
Easy application
Biodegradable
Increases patient compliance
Reduce systemic side effects
More comfortable than ocular inserts
Simple manufacturing process
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FIGURE 3: Gamma scintigraphy dynamic study shows that plain eye drop formulation designed in in situ gel 
formulation ofSparfloxacin improves rate ofdrug release and prolong contact time of drug at the corneal surface. 
Adapted from HimanshuGupta et al.,(2015). 
 
 
 FIGURE 4: Development of in vitro hydrogel with in situ gels and artificial tear fluid using gellan gum as 
polymer adapted from Lina Zhu et al.,(2015). 
 
TABLE 1: Dosage forms, Benefit and Drawback of ocular conventional dosage forms adapted from 
Suryawanshiet al.,(2012). 
 
DOSAGE FORMS BENEFITS DRAWBACKS 
 Solution  Easy to administer. 
 
 Short acting. 
 Rapid nasolacrimal drainage. 
 Frequent instillation. 
 Poor pre-corneal penetration. 
 Loss of drug by drainage. 
Ointment   Prolong drug release. 
 Enhances drug stability. 
 
 
 Blurred vision. 
 Sticking of eyelids. 
 Discomfort. 
 Low patient compliance. 
 Limited drug choice depends on 
partition coefficient. 
 Greasy preparation 
Suspension  Great for drug with slow 
dissolution. 
 Loss of drug in solution and 
suspended solid. 
Emulsion   Prolong drug release from 
the vehicle. 
 Oil entrapment. 
 Low patient compliance. 
 Blurred vision. 
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Gels  Comfortable than ointments.  Matted eyelids. 
 No rate controlling of drug diffuse. 
Ocular inserts  Sophisticated and prolong 
delivery system. 
 Less affected by 
nasolacrimal drainage. 
 Low patient compliance. 
 Discomfort. 
 Abrasion while application. 
 
